Business Context and Reporting Period
This Form 8-K filing by Prelude Therapeutics Inc. (PRLD) is dated March 2, 2021. The report addresses Item 5.02 regarding the determination of annual bonus amounts for the fiscal year ended December 31, 2020, for the Company's named executive officers. These amounts were previously omitted from the Summary Compensation Table in the Company's January 2021 Prospectus because they had not yet been determined.
Key Financial Metrics
The filing does not provide company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation data for the fiscal year 2020 (and 2019 for the CEO). Key compensation figures include:
- Kris Vaddi, Ph.D. (CEO): Total 2020 compensation of $11,632,464, comprising $417,058 in salary, $1,409,998 in stock awards, $9,576,741 in option awards, and $228,667 in non-equity incentive plan compensation (cash bonus).
- Deborah Morosini, M.D. (EVP, Clinical Affairs): Total 2020 compensation of $3,921,302, comprising $194,466 in salary (including prior consulting fees), $3,594,492 in option awards, and $132,344 in cash bonus.
- Christopher Pierce, M.B.A. (EVP, Business Operations): Total 2020 compensation of $3,930,865, comprising $204,029 in salary (including prior consulting fees), $3,594,492 in option awards, and $132,344 in cash bonus.
Material Changes Versus Prior Period
The filing provides a comparative view for the CEO, Kris Vaddi, between 2020 and 2019:
- Total Compensation: Increased from $2,079,400 in 2019 to $11,632,464 in 2020.
- Option Awards: Increased significantly from $828,125 in 2019 to $9,576,741 in 2020.
- Stock Awards: Increased from $815,000 in 2019 to $1,409,998 in 2020.
- Cash Bonus: Increased from $121,275 in 2019 to $228,667 in 2020.
For the other named executive officers, 2019 data is not provided as they joined the company in July 2020.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document is strictly a disclosure of finalized executive compensation figures to update the previously filed Prospectus.
Important Facts for Investor Verification
- Compensation Timing: Verify that the cash bonus amounts for fiscal year 2020 were determined on March 2, 2021, and were not included in the January 2021 Prospectus.
- Valuation Methodology: Confirm that stock and option award values are reported as aggregate grant date fair value computed under FASB ASC Topic 718, which may not reflect actual economic value received.
- Consulting Fees: Note that the salary figures for Dr. Morosini and Mr. Pierce include consulting fees paid prior to their official employment start dates in July 2020.
- Board Compensation: Verify that Dr. Vaddi receives no additional compensation for his role as a member of the Board of Directors.